Christene Huang
Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Swine | 43 | 2024 | 825 | 2.110 |
Why?
| | Diphtheria Toxin | 13 | 2020 | 65 | 1.890 |
Why?
| | Immunotoxins | 12 | 2022 | 55 | 1.750 |
Why?
| | Swine, Miniature | 26 | 2016 | 89 | 1.670 |
Why?
| | Transplantation Chimera | 12 | 2016 | 57 | 1.270 |
Why?
| | Transplantation Conditioning | 9 | 2016 | 191 | 1.130 |
Why?
| | Lymphocyte Depletion | 9 | 2016 | 132 | 1.080 |
Why?
| | Galectin 3 | 3 | 2022 | 21 | 1.080 |
Why?
| | Hematopoietic Stem Cell Transplantation | 12 | 2016 | 699 | 1.040 |
Why?
| | Blood Component Removal | 2 | 2018 | 26 | 1.030 |
Why?
| | Graft Rejection | 12 | 2025 | 521 | 0.990 |
Why?
| | CD3 Complex | 5 | 2013 | 112 | 0.920 |
Why?
| | Graft vs Host Disease | 6 | 2016 | 279 | 0.760 |
Why?
| | Swine Diseases | 5 | 2015 | 9 | 0.740 |
Why?
| | Recombinant Fusion Proteins | 10 | 2020 | 666 | 0.710 |
Why?
| | Transplantation Tolerance | 7 | 2024 | 39 | 0.680 |
Why?
| | Graft Survival | 10 | 2024 | 518 | 0.650 |
Why?
| | Skin Transplantation | 5 | 2016 | 85 | 0.640 |
Why?
| | Lymphoproliferative Disorders | 5 | 2015 | 57 | 0.620 |
Why?
| | Isoantibodies | 5 | 2016 | 57 | 0.600 |
Why?
| | Bone Marrow Transplantation | 7 | 2015 | 298 | 0.590 |
Why?
| | Histocompatibility Antigens | 3 | 2015 | 102 | 0.570 |
Why?
| | Animals | 63 | 2025 | 38030 | 0.550 |
Why?
| | Interleukin-2 | 5 | 2020 | 440 | 0.530 |
Why?
| | Cell Transplantation | 2 | 2010 | 39 | 0.530 |
Why?
| | Transplantation, Homologous | 8 | 2016 | 418 | 0.530 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 409 | 0.500 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 265 | 0.500 |
Why?
| | Immunity, Humoral | 3 | 2015 | 118 | 0.490 |
Why?
| | Lymphocyte Transfusion | 1 | 2016 | 20 | 0.490 |
Why?
| | Transplantation, Haploidentical | 1 | 2016 | 23 | 0.480 |
Why?
| | Receptors, CCR4 | 5 | 2020 | 24 | 0.440 |
Why?
| | T-Lymphocytes | 8 | 2015 | 1996 | 0.430 |
Why?
| | Blood Donors | 1 | 2016 | 144 | 0.430 |
Why?
| | Transplantation Immunology | 4 | 2012 | 29 | 0.430 |
Why?
| | Vascularized Composite Allotransplantation | 2 | 2024 | 30 | 0.410 |
Why?
| | Autoimmunity | 2 | 2022 | 933 | 0.410 |
Why?
| | Cell Lineage | 2 | 2006 | 377 | 0.400 |
Why?
| | Pichia | 8 | 2017 | 19 | 0.400 |
Why?
| | Immunity, Cellular | 3 | 2013 | 274 | 0.380 |
Why?
| | Immunosuppressive Agents | 6 | 2024 | 838 | 0.380 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 5 | 2020 | 82 | 0.370 |
Why?
| | Cyclosporine | 7 | 2016 | 256 | 0.360 |
Why?
| | Tissue Engineering | 1 | 2016 | 439 | 0.360 |
Why?
| | Immune Tolerance | 6 | 2024 | 385 | 0.350 |
Why?
| | Major Histocompatibility Complex | 5 | 2005 | 233 | 0.350 |
Why?
| | Inbreeding | 2 | 2009 | 20 | 0.340 |
Why?
| | Antibodies | 2 | 2012 | 397 | 0.320 |
Why?
| | Transplantation, Heterologous | 4 | 2021 | 170 | 0.320 |
Why?
| | Whole-Body Irradiation | 4 | 2016 | 74 | 0.310 |
Why?
| | Umbilical Cord | 1 | 2010 | 93 | 0.310 |
Why?
| | Hematopoietic Stem Cells | 4 | 2013 | 435 | 0.300 |
Why?
| | Inflammation | 4 | 2022 | 2878 | 0.300 |
Why?
| | Transplantation | 2 | 2012 | 33 | 0.300 |
Why?
| | Flow Cytometry | 11 | 2020 | 1162 | 0.290 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 127 | 0.280 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 45 | 0.280 |
Why?
| | Liver Diseases | 2 | 2022 | 305 | 0.270 |
Why?
| | CTLA-4 Antigen | 3 | 2013 | 105 | 0.270 |
Why?
| | Thymus Gland | 4 | 2015 | 312 | 0.250 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2007 | 103 | 0.240 |
Why?
| | Chimerism | 1 | 2006 | 35 | 0.240 |
Why?
| | Bone Marrow | 2 | 2010 | 306 | 0.240 |
Why?
| | Histocompatibility Antigens Class I | 4 | 2012 | 202 | 0.240 |
Why?
| | Histocompatibility Antigens Class II | 4 | 2012 | 364 | 0.230 |
Why?
| | Fetal Blood | 1 | 2007 | 327 | 0.220 |
Why?
| | Hematologic Neoplasms | 1 | 2007 | 168 | 0.220 |
Why?
| | Galectins | 2 | 2022 | 26 | 0.220 |
Why?
| | Recombinant Proteins | 7 | 2020 | 1368 | 0.220 |
Why?
| | Corneal Transplantation | 1 | 2025 | 17 | 0.220 |
Why?
| | Myocutaneous Flap | 1 | 2024 | 8 | 0.210 |
Why?
| | Rectus Abdominis | 1 | 2024 | 16 | 0.210 |
Why?
| | Iliac Artery | 1 | 2024 | 55 | 0.210 |
Why?
| | Papio | 3 | 2015 | 70 | 0.210 |
Why?
| | Porphyrins | 1 | 2023 | 16 | 0.200 |
Why?
| | Fiber Optic Technology | 1 | 2023 | 23 | 0.200 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 35 | 0.200 |
Why?
| | Tissue Donors | 3 | 2005 | 420 | 0.200 |
Why?
| | Histocompatibility Testing | 5 | 2015 | 123 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2017 | 3542 | 0.190 |
Why?
| | Lymphocyte Culture Test, Mixed | 6 | 2014 | 49 | 0.190 |
Why?
| | Skin | 3 | 2018 | 753 | 0.190 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1505 | 0.190 |
Why?
| | Antibody Specificity | 2 | 2017 | 178 | 0.190 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.180 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 16 | 0.180 |
Why?
| | Muscle Stretching Exercises | 1 | 2022 | 19 | 0.180 |
Why?
| | Yoga | 1 | 2022 | 30 | 0.180 |
Why?
| | Meditation | 1 | 2022 | 34 | 0.180 |
Why?
| | Histocompatibility | 3 | 2015 | 20 | 0.170 |
Why?
| | Leukapheresis | 3 | 2013 | 27 | 0.170 |
Why?
| | Skin Neoplasms | 2 | 2020 | 849 | 0.170 |
Why?
| | Mice, SCID | 5 | 2017 | 369 | 0.170 |
Why?
| | Immunoglobulin G | 2 | 2017 | 892 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 101 | 0.160 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4560 | 0.160 |
Why?
| | Endogenous Retroviruses | 1 | 2021 | 37 | 0.160 |
Why?
| | Spleen | 3 | 2007 | 508 | 0.160 |
Why?
| | Mice, Inbred NOD | 5 | 2017 | 613 | 0.150 |
Why?
| | Colony-Forming Units Assay | 5 | 2006 | 95 | 0.150 |
Why?
| | Amino Acid Sequence | 6 | 2015 | 2129 | 0.150 |
Why?
| | Base Sequence | 6 | 2015 | 2170 | 0.150 |
Why?
| | Hematologic Diseases | 2 | 2012 | 66 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2883 | 0.140 |
Why?
| | Lymphoma | 1 | 2021 | 237 | 0.140 |
Why?
| | B7-1 Antigen | 3 | 2013 | 55 | 0.140 |
Why?
| | Interleukin-3 | 2 | 2011 | 23 | 0.140 |
Why?
| | Time Factors | 7 | 2017 | 7123 | 0.140 |
Why?
| | Kidney Transplantation | 4 | 2005 | 712 | 0.140 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 18 | 0.140 |
Why?
| | Antibodies, Heterophile | 2 | 2015 | 12 | 0.130 |
Why?
| | Antigen-Presenting Cells | 2 | 2016 | 159 | 0.130 |
Why?
| | Postoperative Complications | 3 | 2022 | 2970 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Papio hamadryas | 2 | 2013 | 3 | 0.130 |
Why?
| | Haplotypes | 2 | 2012 | 499 | 0.130 |
Why?
| | Antibody Affinity | 1 | 2017 | 60 | 0.120 |
Why?
| | Heterografts | 2 | 2013 | 143 | 0.120 |
Why?
| | Antigens, CD19 | 1 | 2017 | 128 | 0.120 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 4 | 0.120 |
Why?
| | Gene Expression | 5 | 2012 | 1476 | 0.120 |
Why?
| | Lymphatic Irradiation | 1 | 2015 | 11 | 0.110 |
Why?
| | Immunoconjugates | 1 | 2017 | 138 | 0.110 |
Why?
| | Humans | 27 | 2024 | 145474 | 0.110 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1041 | 0.110 |
Why?
| | B-Lymphocytes | 2 | 2015 | 870 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2022 | 826 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 2013 | 140 | 0.110 |
Why?
| | Rats | 3 | 2025 | 5584 | 0.110 |
Why?
| | Composite Tissue Allografts | 1 | 2014 | 8 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 848 | 0.110 |
Why?
| | Galactosyltransferases | 2 | 2013 | 12 | 0.110 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2012 | 28 | 0.110 |
Why?
| | Lymphocyte Count | 2 | 2022 | 164 | 0.100 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2015 | 112 | 0.100 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 51 | 0.100 |
Why?
| | Retinal Degeneration | 1 | 2014 | 40 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2013 | 57 | 0.100 |
Why?
| | Leukocytes | 1 | 2015 | 296 | 0.100 |
Why?
| | Plasmids | 2 | 2011 | 373 | 0.100 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 452 | 0.100 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2014 | 78 | 0.100 |
Why?
| | Models, Animal | 4 | 2024 | 393 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2024 | 11772 | 0.090 |
Why?
| | Somatosensory Disorders | 1 | 2012 | 2 | 0.090 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 189 | 0.090 |
Why?
| | Mice | 10 | 2022 | 18329 | 0.090 |
Why?
| | DNA Primers | 2 | 2012 | 505 | 0.090 |
Why?
| | Animals, Laboratory | 1 | 2012 | 22 | 0.090 |
Why?
| | Macaca | 1 | 2012 | 66 | 0.090 |
Why?
| | Macaca mulatta | 1 | 2013 | 186 | 0.090 |
Why?
| | Glycosylation | 4 | 2013 | 173 | 0.090 |
Why?
| | Lung Transplantation | 1 | 2015 | 332 | 0.090 |
Why?
| | Edema | 1 | 2012 | 125 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
| | Neoplasm Transplantation | 2 | 2013 | 246 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 125 | 0.090 |
Why?
| | Immunotherapy | 2 | 2013 | 666 | 0.080 |
Why?
| | Platelet Count | 2 | 2013 | 94 | 0.080 |
Why?
| | CD40 Ligand | 1 | 2010 | 40 | 0.080 |
Why?
| | Immunization | 1 | 2012 | 375 | 0.080 |
Why?
| | Prednisolone | 1 | 2010 | 67 | 0.080 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 170 | 0.080 |
Why?
| | Protein Binding | 5 | 2014 | 2238 | 0.080 |
Why?
| | Lymphocytes | 2 | 2021 | 376 | 0.080 |
Why?
| | Blood Proteins | 2 | 2022 | 239 | 0.080 |
Why?
| | Monocytes | 2 | 2003 | 539 | 0.080 |
Why?
| | Leukocytosis | 1 | 2009 | 32 | 0.080 |
Why?
| | Sus scrofa | 2 | 2012 | 65 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 251 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 934 | 0.080 |
Why?
| | Antigens, CD | 2 | 2003 | 558 | 0.080 |
Why?
| | Immunophenotyping | 2 | 2007 | 319 | 0.070 |
Why?
| | Leukocyte Count | 2 | 2012 | 316 | 0.070 |
Why?
| | Pluripotent Stem Cells | 2 | 2014 | 82 | 0.070 |
Why?
| | Cytokines | 3 | 2025 | 2067 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 782 | 0.070 |
Why?
| | Biomarkers | 4 | 2025 | 4295 | 0.070 |
Why?
| | Antigens | 1 | 2010 | 348 | 0.070 |
Why?
| | Cell Line | 4 | 2021 | 2823 | 0.070 |
Why?
| | Bone Marrow Cells | 3 | 2006 | 321 | 0.070 |
Why?
| | Anemia | 1 | 2009 | 191 | 0.070 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 468 | 0.070 |
Why?
| | Macaca fascicularis | 2 | 2018 | 70 | 0.060 |
Why?
| | Prognosis | 3 | 2022 | 4316 | 0.060 |
Why?
| | Varicellovirus | 1 | 2007 | 17 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 167 | 0.060 |
Why?
| | Granulocyte Precursor Cells | 1 | 2006 | 9 | 0.060 |
Why?
| | Haploidy | 1 | 2006 | 28 | 0.060 |
Why?
| | Models, Molecular | 1 | 2011 | 1598 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2010 | 531 | 0.060 |
Why?
| | Species Specificity | 3 | 2015 | 546 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2214 | 0.060 |
Why?
| | Cross Reactions | 2 | 2016 | 130 | 0.050 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1048 | 0.050 |
Why?
| | Cell Separation | 2 | 2002 | 305 | 0.050 |
Why?
| | Allografts | 2 | 2015 | 152 | 0.050 |
Why?
| | Blood Group Incompatibility | 1 | 2004 | 21 | 0.050 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 5 | 0.050 |
Why?
| | Stem Cell Factor | 1 | 2003 | 16 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2003 | 85 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2003 | 16 | 0.050 |
Why?
| | Multipotent Stem Cells | 1 | 2003 | 21 | 0.050 |
Why?
| | Uterus | 1 | 2005 | 227 | 0.050 |
Why?
| | Pregnancy | 4 | 2015 | 7202 | 0.050 |
Why?
| | Granulocytes | 1 | 2003 | 81 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 2022 | 418 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 2023 | 81 | 0.050 |
Why?
| | Hindlimb | 1 | 2004 | 132 | 0.050 |
Why?
| | Female | 8 | 2022 | 78844 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2005 | 196 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2002 | 12 | 0.050 |
Why?
| | Fetal Diseases | 1 | 2005 | 194 | 0.050 |
Why?
| | Binding, Competitive | 2 | 2014 | 185 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2015 | 2507 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2028 | 0.050 |
Why?
| | Oximetry | 1 | 2023 | 125 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2002 | 92 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2007 | 4148 | 0.040 |
Why?
| | Male | 8 | 2025 | 72842 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2002 | 177 | 0.040 |
Why?
| | Lung | 1 | 2015 | 4106 | 0.040 |
Why?
| | Gammaherpesvirinae | 1 | 2002 | 45 | 0.040 |
Why?
| | Patient Acuity | 1 | 2022 | 48 | 0.040 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 119 | 0.040 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 104 | 0.040 |
Why?
| | Solubility | 2 | 2012 | 240 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 95 | 0.040 |
Why?
| | Neoplasms | 1 | 2017 | 2906 | 0.040 |
Why?
| | Gestational Age | 1 | 2005 | 987 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 172 | 0.040 |
Why?
| | Protein Multimerization | 2 | 2014 | 204 | 0.040 |
Why?
| | Fetus | 1 | 2005 | 804 | 0.040 |
Why?
| | Rabbits | 2 | 2013 | 652 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 574 | 0.040 |
Why?
| | Genome, Viral | 1 | 2002 | 214 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 90 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 231 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 287 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 2 | 2013 | 471 | 0.040 |
Why?
| | Viral Proteins | 1 | 2022 | 350 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 499 | 0.040 |
Why?
| | DNA | 2 | 2017 | 1435 | 0.040 |
Why?
| | Risk | 1 | 2022 | 919 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 506 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2002 | 1132 | 0.030 |
Why?
| | Oxygen | 1 | 2023 | 978 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2017 | 3124 | 0.030 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2017 | 2 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2121 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 325 | 0.030 |
Why?
| | Herpesvirus 1, Suid | 1 | 2015 | 2 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 886 | 0.030 |
Why?
| | Tumor Virus Infections | 1 | 2015 | 51 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2015 | 69 | 0.030 |
Why?
| | National Eye Institute (U.S.) | 1 | 2014 | 6 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2930 | 0.030 |
Why?
| | Cell Engineering | 1 | 2014 | 15 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1100 | 0.030 |
Why?
| | Regenerative Medicine | 1 | 2014 | 48 | 0.020 |
Why?
| | Random Allocation | 1 | 2014 | 365 | 0.020 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2013 | 14 | 0.020 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 124 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2013 | 89 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2013 | 246 | 0.020 |
Why?
| | Hematocrit | 1 | 2013 | 108 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2014 | 223 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 145 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 376 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2012 | 61 | 0.020 |
Why?
| | Drug Design | 1 | 2013 | 175 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1179 | 0.020 |
Why?
| | Lymph Nodes | 2 | 2005 | 503 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 462 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 354 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 10885 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1997 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 8057 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 652 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1061 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 971 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2007 | 1454 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 72 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2007 | 244 | 0.010 |
Why?
| | Open Reading Frames | 1 | 2007 | 130 | 0.010 |
Why?
| | Splenectomy | 1 | 2005 | 61 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3747 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2022 | 17291 | 0.010 |
Why?
| | Middle Aged | 2 | 2022 | 36215 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 288 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5983 | 0.010 |
Why?
| | Creatinine | 1 | 2005 | 515 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 692 | 0.010 |
Why?
| | Adult | 2 | 2022 | 40777 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 409 | 0.010 |
Why?
| | Hybridomas | 1 | 2002 | 233 | 0.010 |
Why?
| | Genes, Viral | 1 | 2002 | 88 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 387 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2002 | 362 | 0.010 |
Why?
| | Aged | 1 | 2022 | 26153 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1923 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 207 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 538 | 0.010 |
Why?
| | Bone and Bones | 1 | 2004 | 317 | 0.010 |
Why?
| | Cell Adhesion | 1 | 2002 | 451 | 0.010 |
Why?
| | Benzimidazoles | 1 | 2002 | 189 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 756 | 0.010 |
Why?
| | Mammals | 1 | 2002 | 286 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 333 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 926 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 440 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 777 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2803 | 0.010 |
Why?
| | Phylogeny | 1 | 2002 | 917 | 0.010 |
Why?
| | Kidney | 1 | 2005 | 1497 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2923 | 0.010 |
Why?
| | United States | 1 | 2014 | 16098 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 956 | 0.010 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|